9 July 2026 in European Heart Journal
Background and Aims: Chronological age is central to cardiovascular disease (CVD) risk estimation but poorly reflects interindividual heterogeneity in cardiovascular aging. This study developed a peri-aortic adipose tissue (PAAT) radiomic cardiovascular age (CV-Age) biomarker from routine chest CT and tested whether the PAAT age gap (ΔAge = CV-Age − chronological age) stratifies major adverse cardiovascular events (MACE) and improves risk classification. Methods: Four chest CT cohorts with different protocols were utilized to train (n = 4451) and externally validate (n = 44 214) a CV-Age model. Associations between ΔAge decile groups (resilient ≤10th; accelerated ≥90th) and incident 5-point MACE (myocardial infarction, stroke, revascularization, heart failure, and death) were assessed using survival models. Clinical utility was evaluated by substituting CV-Age for chronological age in PREVENT to quantify risk reclassification. Results: A 31-feature radiomic signature capturing PAAT volume, attenuation, and texture heterogeneity predicted age with good accuracy (training MAE 2.2 years; primary external validation MAE 2.7 years). In a separate higher-risk cohort, predictions showed a positive ΔAge (median +5.4 years), reflecting elevated baseline cardiovascular burden. ΔAge-stratified event-free survival differed across groups (log-rank P < .001); compared with normative agers, accelerated agers had higher MACE risk (HR 1.51, 95% CI 1.37–1.66), and resilient agers had lower risk (HR 0.70, 0.63–0.77). Substituting CV-Age into PREVENT improved risk reclassification (categorical NRI +0.03, P < .01, continuous NRI +0.04, P < .05). Conclusions: Radiomic profiling of PAAT on routine chest CT yields a scalable imaging biomarker of cardiovascular aging. CV-Age can help improve identification of higher-risk individuals missed by age-driven risk estimation, supporting its role as a risk-enrichment tool.
13 November 2026 in European Heart Journal - Cardiovascular Imaging
Aims: Heart failure (HF) prevention remains limited because early multisystem cardiometabolic dysfunction is not captured by conventional risk tools. We evaluated whether liver radiomic phenotypes derived opportunistically from coronary artery calcium computed tomography (CAC-CT) identify imaging-defined hepatic stress states associated with incident HF. Methods and results: We analysed 59 237 individuals undergoing CAC-CT (CLARIFY: 46 028; Houston Methodist: 13 209). Liver regions were segmented and radiomic features extracted to derive a Liver Radiomics Score (LRS). The model was trained in a CLARIFY derivation cohort (Dtr, n = 9205), validated in a hold-out cohort (Dts, n = 36 823), and externally evaluated in Houston Methodist (Dext, n = 13 209). The mean follow-up was 1411 days (SD 760.1) in the pooled Dtr and Dts cohorts (1144 HF events) and 470 days (SD 596) in Dext (212 HF events). Continuous LRS was associated with incident HF [Dts: hazard ratio (HR) 1.63, 95% confidence interval (CI) 1.52–1.74; P < 0.001; Dext: HR 1.04, 95% CI 1.01–1.07; P = 0.004] and remained significant after multivariable adjustment in Dts. Increasing LRS quartiles showed progressively adverse hepatic, haemodynamic, and cardiometabolic profiles and higher HF risk. Among 17 806 Dts participants with PREVENT data, adding LRS modestly improved discrimination across CAC- and PREVENT-based models (P < 0.001) and improved reclassification metrics (7-year net reclassification improvement up to 0.25; including integrated discrimination improvement up to 0.015). High LRS identified elevated risk in low-risk groups: among participants with CAC=0, high LRS conferred ∼2.5-fold higher 5-year HF incidence, and ∼2.9-fold in PREVENT-low individuals. Conclusion: In this large multicentre cohort, liver radiomics from CAC-CT captured hepatic stress states linked to HF risk and modestly improved risk stratification beyond CAC and PREVENT scores.